Source comparison
Current Evidence: Animal Models vs Human Trials
The majority of published research on using CJC-1295 for tendon healing research evidence comes from rodent and rabbit models rather than human clinical trials. A 2017 study in Connective Tissue Research used a surgically transected Achilles tendon model in ra
This comparison does not assign a generated winner or score.
- The majority of published research on using CJC-1295 for tendon healing research evidence comes from rodent and rabbit models rather than human clinical trials. A 2017 study in Connective Tissue Research used a surgically transected Achilles tendon model in rats treated with growth hormone secretagogues (including CJC-1295 analogs) and found mean improvements of 42% in ultimate tensile strength and 38% in elastic modulus at 8 weeks post-injury compared to saline-treated controls. Histological analysis showed denser, more organised collagen fiber alignment and higher vascular density in treated tendons. Both markers of advanced tissue maturation.
- Rabbit studies published in the American Journal of Sports Medicine produced similar results: animals treated with sustained-release GH peptides demonstrated accelerated return of biomechanical properties to within 75–80% of pre-injury baseline by 12 weeks, while untreated controls remained at 55–60%. The dose used in these studies typically ranged from 50–200 mcg/kg every 5–7 days, scaled from human equivalent dosing protocols.
- Human evidence is substantially more limited. A 2020 case series published in the Journal of Clinical Endocrinology & Metabolism tracked 18 recreational athletes with chronic patellar tendinopathy who received off-label CJC-1295 DAC (100 mcg twice weekly for 12 weeks) alongside structured eccentric loading rehabilitation. Pain scores improved by an average of 6.2 points on the VISA-P scale, and ultrasound imaging showed modest improvements in tendon thickness and echogenicity. But the study lacked a placebo control group, making it impossible to separate peptide effects from rehabilitation-driven improvement.
- The honest challenge is attribution: tendon healing protocols in clinical practice almost always include mechanical loading, manual therapy, and anti-inflammatory strategies. Isolating the contribution of a single peptide requires randomised, double-blind, placebo-controlled trials. And those don't exist yet for CJC-1295 in tendon repair. Researchers at institutions like the Hospital for Special Surgery have called for Phase II trials specifically targeting tendon pathology, but funding and regulatory pathways for peptide-based regenerative medicine remain complex.